Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.37 |
| ▸ | CTSL | P07711 | 12/20 | 0.37 |
| ▸ | CTSS | P25774 | 8/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 3/20 | 0.34 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318514 | 0.89 | MAPK1 (0.36) | CTSKCTSLCTSSLMNARAB9A | |
| SCHEMBL6213890 | 0.88 | CTSB (0.34) | CTSKCTSLCTSSSMN1; SMN2KMT2A | |
| SCHEMBL4768354 | 0.88 | CTSB (0.34) | CTSKCTSLCTSSSMN1; SMN2KMT2A | |
| SCHEMBL7426317 | 0.86 | CTSK (0.37) | CTSKCTSLCTSSLMNARAB9A | |
| SCHEMBL6212013 | 0.86 | CTSK (0.40) | CTSKCTSLCTSSRAB9ASMN1; SMN2 | |
| SCHEMBL6214202 | 0.84 | CTSK (0.47) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6215050 | 0.84 | CTSK (0.36) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4315427 | 0.77 | MAPK1 (0.40) | CTSKCTSLCTSSLMNAMAPK1 | |
| SCHEMBL6213555 | 0.77 | CTSL (0.38) | CTSKCTSLCTSS | |
| SCHEMBL5971691 | 0.76 | MAPK1 (0.36) | CTSKCTSLCTSSLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | claimed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
| WO-2003045909-A2 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF AZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885CTSL 11/4885CTSS 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.